Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Yuanhuadine (CAS No.: 76402-66-9) is a type of compound derived from the traditional Chinese medicinal herb Yuanhua (Daphne genkwa Sieb. et Zucc.). As a traditional Chinese medicine, coriander has long been used to treat various diseases, especially showing remarkable pharmacological activity in anti-tumor, anti-inflammatory, and immunomodulatory properties. As one of its main active ingredients, cosmester ethyl has attracted widespread attention in recent years due to its unique chemical structure and multi-target biological activity. Numerous studies have shown that coriander ester ethyl shows promising potential in the anti-tumor field, capable of inhibiting tumor cell proliferation, inducing apoptosis, and suppressing tumor metastasis by regulating various signaling pathways and molecular targets. This paper will systematically review the chemical structure and physicochemical properties of Coriander Ester B, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, and explore its clinical application prospects and development directions, aiming to provide theoretical basis and research reference for the pharmacology of natural products and the development of antitumor drugs.
Cilantro ester ethyl is a natural product with a molecular weight of 586.6780 and a relatively complex chemical structure. Its molecular structure contains multiple ester groups and aromatic rings, giving it unique biological activity. Its LogP value is 2.7052, indicating that the compound has moderate lipid solubility, which facilitates cell membrane penetration and distribution in vivo. The total polar surface area (TPSA) is 144.2800, showing certain polar characteristics that have an important impact on its binding to protein targets. Low water solubility (0.0208 mg/mL) suggests limited solubility in the aqueous phase, which may affect its bioavailability. Notably, corydalis ethyl has a high blood-brain barrier penetration ability, offering potential applications in central nervous system-related diseases. The hERG channel inhibition test result was negative, indicating a low risk of cardiotoxicity. The Ames test result was 0.6, indicating a low genotoxicity risk and good safety.
Coriander ester B mainly comes from the coriander plant, which belongs to the genus Daphne in the Thymelaeaceae family, widely distributed in southern China and Southeast Asia. The roots, stems, and flowers of coriander all contain abundant active components, with the highest concentrations found in the roots and flowers. Traditionally, coriander is mostly used medicinally from dried roots or flowers, with effects of dispelling wind and cold, reducing swelling, and relieving pain.
The process for extracting corylon ester ethyl mainly includes solvent extraction and chromatographic separation. The commonly used extraction solvents are ethanol or methanol, and extraction efficiency is improved by ultrasound-assisted extraction or reflux extraction methods. After concentration, the extract was separated and purified using silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC). In recent years, with advances in separation technology, supercritical fluid extraction and molecular blotting techniques have also been applied to the efficient extraction and purification of coriander ester ethylene, significantly improving yield and purity.
Pharmacological activity studies of corynophenyl ester B mainly focus on its antitumor effects. In vitro cell experiments have shown that corydal ester B can significantly inhibit the proliferation of various tumor cell lines, including lung cancer, breast cancer, liver cancer, and colorectal cancer. Its inhibitory effect is dose-dependent, with IC50 values generally in the low micromolar range, indicating high cytotoxicity.
In vivo experiments, corynosteryl acid B was administered intraperitoneally or orally, significantly slowing tumor growth, reducing tumor volume, and causing relatively low toxic side effects on normal tissue. Its anti-tumor activity is not only reflected in inhibiting tumor cell proliferation, but also in inducing tumor cell apoptosis, blocking the cell cycle process, and suppressing tumor angiogenesis and metastasis.
In addition, cilantro ester ethyl exhibits anti-inflammatory and immunomodulatory effects, helping to regulate the tumor microenvironment and enhance the body's immune surveillance function. These multiple pharmacological effects lay a solid foundation for its development as an antitumor drug.
The antitumor mechanism of cosmein ester ethyl involves multiple signaling pathways and several key molecular targets. Research shows that coriander ester can regulate the following main targets:
MCL1 and BCL2: As members of the anti-apoptotic protein family, MCL1 and BCL2 are highly expressed in tumor cells, promoting cell survival. Vitamin E corylon promotes tumor cell apoptosis by downregulating its expression.
STAT3: Signal transduction and transcription activator 3 (STAT3) is abnormally activated in various tumors, promoting tumor cell proliferation and immune evasion. Acetophosphate inhibits phosphorylation of STAT3, blocking its signal transduction.
MMP2: Matrix metalloproteinase 2 (MMP2) is involved in tumor cell invasion and metastasis. Corydorium ester inhibits the expression and activity of MMP2, reducing the potential for tumor metastasis.
TOP1 and TOP2A: Topoisomerases 1 and 2A are important enzymes for DNA replication and transcription. Coriander E-E inhibits its activity, interferes with tumor cell DNA metabolism, and inhibits cell proliferation.
HIF1A: Hypoxia-inducing factor 1α regulates tumor cells' adaptation to hypoxic environments and promotes angiogenesis. Corydalis ester inhibits HIF1A expression and blocks tumor angiogenesis.
MAPK1: Mitogen-activated protein kinase 1 participates in cell proliferation and differentiation signaling; colanum ester ethyl regulates its activity and influences tumor cell growth.
ESR1 and CYP19A1: Estrogen receptor α (ESR1) and aromatase (CYP19A1) play important roles in hormone-dependent tumors. Corydalis ester E affects hormone signaling pathways by regulating their expression.
In summary, corylon ester ethyl demonstrates broad-spectrum anti-tumor potential through multi-target and multi-pathway synergistic effects to comprehensively regulate tumor cell growth, apoptosis, invasion, and microenvironment.
The druggability evaluation of Cilanthalide B indicates it has good potential for drug development. It has a moderate molecular weight, a LogP value suitable for cell membrane penetration, and high blood-brain barrier permeability, making it suitable for developing central nervous system-related indications. Additionally, hERG channels showed no significant inhibitory effect, suggesting a low risk of cardiotoxicity. Ames test results showed that it has low genotoxicity and good safety.
However, coryon ester B has relatively low water solubility, which may limit its oral bioavailability. To address this issue, researchers have attempted to use drug delivery systems such as nanocarriers, liposome encapsulation, and solid dispersions to improve their solubility and in vivo stability.
Pharmacokinetic studies show that coriander ester B is widely distributed in the body, has a moderate half-life, and can effectively reach therapeutic concentrations. Its metabolic pathway mainly involves biological transformation through hepatic enzyme systems, and the activity and safety of these metabolites still require further exploration. In the future, further systematic pharmacokinetics and toxicology studies are needed to provide a basis for clinical translation.
Based on the multi-target effect and good safety profile of corynophenyl ester in the field of anti-tumors, its future clinical application prospects are broad. First, colantro ester ethyl can be used as a single drug to treat various solid tumors, especially showing potential efficacy for tumors resistant to traditional chemotherapy. Second, corynophenyl esteroid B combined with existing antitumor drugs may produce a synergistic effect, enhancing efficacy and reducing toxic side effects. Moreover, given its blood-brain barrier penetration, corydal estyl ethyl has unique advantages in treating brain tumors and neurological tumors.
Future research should focus on optimizing drug formulations, addressing solubility and bioavailability issues, and conducting systematic preclinical safety evaluations and efficacy verification. At the same time, it is important to deeply analyze its mechanisms of action and uncover more potential targets to support precision treatment. Multicenter, large-sample clinical trials will be a key step in verifying their clinical value.
As an important active ingredient in coriander, Cilant Ester E, with its unique chemical structure and multi-target anti-tumor effects, demonstrates remarkable pharmacological activity and good druggability. Its multiple mechanisms in regulating tumor cell proliferation, apoptosis, and metastasis provide valuable examples for the development of natural anti-tumor drugs. Although there are still certain challenges in pharmacokinetics and clinical applications, with continuous advances in extraction and purification technology, drug delivery systems, and molecular pharmacology research, cosmetyl ester B is expected to become an important candidate for the new generation of antitumor drugs. Future research should strengthen both preclinical and clinical studies, promote clinical translation, and benefit more cancer patients.
